Global spending on medicines will reach $1.4 trillion in 2020, driven by increased healthcare access in emerging markets and high-priced new drugs for cancer and other diseases, according to a forecast by IMS Health released on Wednesday. That is up from about $1.07 trillion this year, representing a compound annual growth rate of 4 to 7 percent over the next five years, the "Global Medicines Use in 2020" report compiled by IMS Institute for Healthcare Informatics found. Some 225 new drugs will
NAI500 Comments: i. The Chinese government is heavily focused on the health of its citizens as shown by its decision to build 7,500 public hospitals through the private sector over the next decade. ii. China’s health challenges include significantly high rates of smoking, high pollution levels, and a rapidly aging population. iii. Given China’s healthcare challenges, Canadian healthcare developers should target cancer treatment, heart disease treatment, and age related solutions. iv. The cit
South Korean biotech Genexine Inc. licensed out three of its compounds for $100 million to a Chinese drug developer, exploring the Asian market for next-generation long-acting growth hormone treatments. Clinical-stage Genexine (KOSDAQ:095700) signed a licensing and technology transfer agreement with China's Tasgen, a subsidiary of Tasly Pharmaceutical Group Co. Ltd. (SH:600535). Under the deal reached this week, Genexine will grant the China rights for three compounds, GX-H9, GX-G6 and GX-G3, to Tasgen i
Chinese pharmaceutical firm GZ Bailing Group Pharm. Co. [SHE:002424] said in a statement that it will boost an herbal medicine company’s competitiveness by investing in it. T...
Diamedica Inc is a development stage biopharmaceutical company. The Company is engaged in the dis...
Trxade Group Inc, formerly Xcellink International Inc. develops patented business process that pr...
Kane Biotech is a Canadian-based biotechnology company engaged in the development and commerciali...
Gilber Chan, the President of NAI500, presents the latest speech of 2016 investment strategy on Global Chinese Financial Forum - Vancouver Conference 2016: The Top 10 Developments...
China's policymakers still have ammunition to counter the mainland's slowing economy, including supply-side reforms and subsidized housing, HSBC said. In a note released Tu...
Consumer staples and services, health care, software and auto stocks are Henderson Global Investors' top Chinese stock picks for 2016 — but don't get your hopes up for a...
The leaders of the world's largest economies stuck to a goal of lifting their collective output by an extra 2 percent by 2018, even though growth remains uneven and weaker than expect...
The renminbi's status as a global reserve currency may be effectively guaranteed following formal backing by International Monetary Fund (IMF) staff, according to economists, but trad...
today announced financial results for the quarter ended March 31, 2017 and provided a business update. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "...
today announced the publication of a research paper entitled "Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer". The study was...
today highlighted two additional works involving its lead drug, apabetalone, one recently published by third party academics and one in the form of a patent application by Pfizer Inc. (Pf...
|Company Name||Symbol||Price||Change||Vol(k)||Day's Range||Contact|
|1||AEterna Zentaris Inc||NASDAQ:AEZS||1.122||
||1616571||0.9501 - 1.2100|
|2||MEI Pharma Inc||NASDAQ:MEIP||2.150||
||613785||1.9500 - 2.1500|
|3||Cellular Biomedicine Group Inc||NASDAQ:CBMG||5.900||
||24598||5.70 - 6.05|
|4||Avita Medical Ltd||OTCMKTS:AVMXY||1.480||
||8320||1.34 - 1.48|
|5||Titan Medical Inc||TSX:TMD||0.360||
||101670||0.35 - 0.37|
||3022||3.36 - 3.53|
|7||OncoGenex Pharmaceuticals Inc||NASDAQ:OGXI||0.370||
||22627||0.3502 - 0.3700|
||466465||1.2500 - 1.3100|
|9||Windtree Therapeutics Inc||NASDAQ:WINT||0.950||
||4789||0.91 - 0.95|
|10||TG Therapeutics Inc||NASDAQ:TGTX||12.269||
||406760||11.800 - 12.500|
||15770||0.7014 - 0.7400|
|12||Supernus Pharmaceuticals Inc||NASDAQ:SUPN||35.100||
||120598||34.35 - 35.45|
||300||1.95 - 1.95|
|14||Cardiome Pharma Corp||NASDAQ:CRME||4.230||
||11830||4.15 - 4.25|
|15||Sunesis Pharmaceuticals Inc||NASDAQ:SNSS||3.140||
||6816||3.03 - 3.14|